Latest News and Press Releases

CAMBRIDGE, Mass., June 04, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...

NEW YORK, NY, Jan. 27, 2020 (GLOBE NEWSWIRE) -- PharmaCyte Biotech (OTCQB: PMCB) announced that its clinical trial product, which will be employed during the company’s upcoming Phase 2b clinical...

WASHINGTON, Jan. 08, 2020 (GLOBE NEWSWIRE) -- On December 23, 2019, Celgene backed out of a settlement in which it had agreed to pay $55 million to end payors (consumers, insurers, union health and...

- Initiated Phase 2 EMERGE trial of vopratelimab - - Completed enrollment of Phase 1 trial of JTX-4014 - - Updated strategic collaboration and established new licensing agreement with...

WASHINGTON, July 24, 2019 (GLOBE NEWSWIRE) -- Hausfeld, a global claimants’ law firm dedicated to handling complex litigation, announced today that it has reached a $55 million settlement with...

- Celgene licenses JTX-8064, resulting in $50.0 million upfront payment to Jounce - - Jounce retains full worldwide rights to vopratelimab, JTX‑4014 and all discovery programs - - Company to host...

CAMBRIDGE, Mass., April 17, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...

NEW YORK, NY, Feb. 04, 2019 (GLOBE NEWSWIRE) -- Clinical stage biotechnology company PharmaCyte Biotech (OTCQB: PMCB) is now closer than ever to reaching what would be a monumental milestone in the...

Toronto, ON, Jan. 29, 2019 (GLOBE NEWSWIRE) -- Triphase Accelerator, a Toronto-based drug development company, has entered into a new strategic partnership with Celgene Corporation. The focus of the...

NEW YORK, NY, Jan. 23, 2019 (GLOBE NEWSWIRE) -- With PharmaCyte Biotech, Inc.’s (OTCQB: PMCB) naming of Medpace, Inc., a global full-service clinical contract research organization (CRO) to conduct...